Below are the most recent publications written about "Antibodies, Neutralizing" by people in Profiles.
-
Espino AM, Armina-Rodriguez A, Alvarez L, Ocasio-Malav? C, Ramos-Nieves R, Rodriguez Martin? EI, L?pez-Marte P, Torres EA, Sariol CA. The Anti-SARS-CoV-2 IgG1 and IgG3 Antibody Isotypes with Limited Neutralizing Capacity against Omicron Elicited in a Latin Population a Switch toward IgG4 after Multiple Doses with the mRNA Pfizer-BioNTech Vaccine. Viruses. 2024 Jan 26; 16(2).
-
Elko EA, Mead HL, Nelson GA, Zaia JA, Ladner JT, Altin JA. Recurrent SARS-CoV-2 mutations at Spike D796 evade antibodies from pre-Omicron convalescent and vaccinated subjects. Microbiol Spectr. 2024 Feb 06; 12(2):e0329123.
-
Buck AM, Deitchman AN, Takahashi S, Lu S, Goldberg SA, Bodansky A, Kung A, Hoh R, Williams MC, Kerbleski M, Maison DP, Deveau TM, Munter SE, Lombardo J, Wrin T, Petropoulos CJ, Durstenfeld MS, Hsue PY, Kelly JD, Greenhouse B, Martin JN, Deeks SG, Peluso MJ, Henrich TJ. The breadth of the neutralizing antibody response to original SARS-CoV-2 infection is linked to the presence of Long COVID symptoms. J Med Virol. 2023 11; 95(11):e29216.
-
Schuelke MR, Bassiri H, Behrens EM, Canna S, Croy C, DiNofia A, Gollomp K, Grupp S, Lambert M, Lambrix A, Maude SL, Myers R, Newman H, Petrosa W, Seif A, Sullivan KE, Teachey DT, Diorio C. Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients. Blood Adv. 2023 09 26; 7(18):5603-5607.
-
Ogundiran AI, Chang T-L, Ivanov A, Kumari N, Nekhai S, Chandran PL. Shear-reversible clusters of HIV-1 in solution: stabilized by antibodies, dispersed by mucin. J Virol. 2023 10 31; 97(10):e0075223.
-
Branche AR, Rouphael NG, Losada C, Baden LR, Anderson EJ, Luetkemeyer AF, Diemert DJ, Winokur PL, Presti RM, Kottkamp AC, Falsey AR, Frey SE, Rupp R, B?cker M, Novak RM, Walter EB, Jackson LA, Little SJ, Immergluck LC, Mahgoub SM, Whitaker JA, Babu TM, Goepfert PA, Fusco DN, Atmar RL, Posavad CM, Netzl A, Smith DJ, Telu K, Mu J, Makowski M, Makhene MK, Crandon S, Montefiori DC, Roberts PC, Beigel JH. Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial. Clin Infect Dis. 2023 08 22; 77(4):560-564.
-
Dai YC, Lin YC, Ching LL, Tsai JJ, Ishikawa K, Tsai WY, Chen JJ, Nerurkar VR, Wang WK. Determining the Time of Booster Dose Based on the Half-Life and Neutralization Titers against SARS-CoV-2 Variants of Concern in Fully Vaccinated Individuals. Microbiol Spectr. 2023 08 17; 11(4):e0408122.
-
Palermo PM, Orbegozo J, Watts DM, Morrill JC. Serosurveillance for Severe Acute Respiratory Syndrome Coronavirus 2 Antibody in Feral Swine and White-Tailed Deer in Texas. Vector Borne Zoonotic Dis. 2023 07; 23(7):397-400.
-
Powers JM, Lyski ZL, Weber WC, Denton M, Streblow MM, Mayo AT, Haese NN, Nix CD, Rodr?guez-Santiago R, Alvarado LI, Rivera-Amill V, Messer WB, Streblow DN. Infection with chikungunya virus confers heterotypic cross-neutralizing antibodies and memory B-cells against other arthritogenic alphaviruses predominantly through the B domain of the E2 glycoprotein. PLoS Negl Trop Dis. 2023 03; 17(3):e0011154.
-
Young E, Yount B, Pantoja P, Henein S, Meganck RM, McBride J, Munt JE, Baric TJ, Zhu D, Scobey T, Dong S, Tse LV, Martinez MI, Burgos AG, Graham RL, White L, DeSilva A, Sariol CA, Baric RS. A live dengue virus vaccine carrying a chimeric envelope glycoprotein elicits dual DENV2-DENV4 serotype-specific immunity. Nat Commun. 2023 03 13; 14(1):1371.